Genka S, Shitara N, Nakamura H, Takakura K
Department of Neurosurgery, University of Tokyo Hospital, Japan.
Neurol Med Chir (Tokyo). 1993 May;33(5):295-9. doi: 10.2176/nmc.33.295.
Fifty-two patients with malignant astrocytoma were treated with cellular synchronization radiation therapy at the University of Tokyo Hospital between 1977 and 1989. Twenty-five patients (Group 1) received 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3- nitrosourea hydrochloride (ACNU), vincristine, and 60 Gy of irradiation, and 27 patients (Group 2) ACNU, vincristine, the Ca-channel blocker nicardipine, and 72 Gy of irradiation. Median survival times for Groups 1 and 2 were 15 and 30 months, respectively. Although there was no significant difference, Group 2 achieved longer survival with 1-, 2-, and 3-year survival rates of 85.2, 65.8, and 46.9% compared to rates of 66.7, 40.0, and 26.7%, respectively, for Group 1.
1977年至1989年间，东京大学医院对52例恶性星形细胞瘤患者进行了细胞同步放射治疗。25例患者（第1组）接受了盐酸1-(4-氨基-2-甲基-5-嘧啶基)甲基-3-(2-氯乙基)-3-亚硝基脲（ACNU）、长春新碱和60 Gy的照射，27例患者（第2组）接受了ACNU、长春新碱、钙通道阻滞剂尼卡地平以及72 Gy的照射。第1组和第2组的中位生存时间分别为15个月和30个月。虽然没有显著差异，但第2组的生存期更长，其1年、2年和3年生存率分别为85.2%、65.8%和46.9%，而第1组分别为66.7%、40.0%和26.7%。
